IPHA
Innate Pharma S.A.
Price Chart
Latest Quote
$1.86
-0.04 (-2.11%)
Current Price
| Previous Close | $1.90 |
| Open | $1.78 |
| Day High | $1.86 |
| Day Low | $1.78 |
| Volume | 5,946 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 93.90M |
| Total Debt | $25.69M |
| Cash Equivalents | $39.04M |
| Revenue | $10.25M |
| Net Income | $-55.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $174.66M |
| EPS (TTM) | $-0.63 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $166.46M |
| Sales | $10.25M |
| Income | $-55.96M |
| Book/sh | $-0.26 |
| Cash/sh | $0.37 |
| Employees | 164 |
Financial Ratios
| Quick Ratio | 1.14 |
| Current Ratio | 1.27 |
Returns & Margins
| ROA | -38.85% |
| Operating Margin | -689.55% |
Ownership
| Insider Ownership | 1.67% |
| Institutional Ownership | 0.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.94 |
| P/S | 19.40 |
| P/B | -7.05 |
Analyst Data
| Recommendation | none |
| Target Price | $6.00 |
Technical Indicators
| SMA20 | $1.79 |
| SMA50 | $1.69 |
| SMA200 | $1.76 |
| RSI | 58.97 |
| ATR | 0.0889 |
| Shares Float | 70.54M |
| Short Float | 0.21% |
| Short Ratio | 1.32 |
| Volatility | 0.89 |
| Rel Volume | 0.16 |
Performance History
| Week | +4.49% |
| Month | +8.14% |
| Quarter | +45.31% |
| 6 Months | +3.91% |
| YTD | +2.20% |
| Year | +3.91% |
| 3 Years | -41.69% |
| 5 Years | -49.87% |
| 10 Years | -69.26% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.86 | 5,946 |
| 2026-06-24 | $1.90 | 11,800 |
| 2026-06-23 | $1.89 | 11,700 |
| 2026-06-22 | $1.81 | 8,700 |
| 2026-06-18 | $1.81 | 1,700 |
| 2026-06-17 | $1.78 | 13,400 |
| 2026-06-16 | $1.79 | 18,000 |
| 2026-06-15 | $1.79 | 42,700 |
| 2026-06-12 | $1.76 | 439,300 |
| 2026-06-11 | $1.74 | 31,100 |
| 2026-06-10 | $1.75 | 5,900 |
| 2026-06-09 | $1.77 | 2,000 |
| 2026-06-08 | $1.76 | 13,300 |
| 2026-06-05 | $1.71 | 5,600 |
| 2026-06-04 | $1.79 | 8,200 |
| 2026-06-03 | $1.76 | 19,600 |
| 2026-06-02 | $1.82 | 38,500 |
| 2026-06-01 | $1.78 | 47,500 |
| 2026-05-29 | $1.83 | 10,500 |
| 2026-05-28 | $1.74 | 11,800 |
| 2026-05-27 | $1.75 | 27,700 |
| 2026-05-26 | $1.72 | 40,300 |
About Innate Pharma S.A.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
đ° Latest News
Innate Pharma Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T16:07:22Z
How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And âŦ8 Target
Simply Wall St. âĸ 2026-03-27T06:06:39Z
Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-26T19:00:56ZInnate Pharma Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-26T15:08:16Z
Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy
MT Newswires âĸ 2025-11-10T09:45:58ZInnate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks âĸ 2025-11-06T14:55:02Z
How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions
Simply Wall St. âĸ 2025-09-20T12:21:56Z
Target initiated, Nike upgraded: Wall Street's top analyst calls
The Fly âĸ 2025-09-18T13:38:40Z
Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...
GuruFocus.com âĸ 2025-09-18T07:00:54Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $3,165,966 | $14,337,158 | $58,958,311 | $56,321,710 |
| Operating Revenue | $2,596,842 | $14,273,543 | $58,945,815 | $57,022,607 |
| Expenses | ||||
| Interest Expense | $499,830 | $642,963 | $727,025 | $327,161 |
| Total Expenses | $63,855,505 | $72,926,277 | $73,349,996 | $74,980,122 |
| Other Income Expense | $3,827,104 | $263,547 | $2,910,372 | $-47,489,493 |
| Net Non Operating Interest Income Expense | $997,387 | $2,125,412 | $2,881,972 | $293,082 |
| Interest Expense Non Operating | $499,830 | $642,963 | $727,025 | $327,161 |
| Operating Expense | $63,855,505 | $72,926,277 | $73,349,996 | $74,980,122 |
| Other Operating Expenses | $1,809,610 | $322,617 | $-3,635,124 | $-148,813 |
| General And Administrative Expense | $12,494,604 | $13,555,606 | $13,345,451 | $16,440,986 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-65,854,824 |
| Net Interest Income | $997,387 | $2,125,412 | $2,881,972 | $293,082 |
| Interest Income | $1,497,217 | $2,768,374 | $3,608,997 | $620,243 |
| Normalized Income | $-59,691,016 | $-56,461,435 | $-11,509,713 | $-18,365,330 |
| Net Income From Continuing And Discontinued Operation | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-66,003,637 |
| Total Operating Income As Reported | $-61,351,813 | $-58,587,983 | $-14,391,685 | $-65,233,445 |
| Net Income Common Stockholders | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-66,003,637 |
| Net Income | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-66,003,637 |
| Net Income Including Noncontrolling Interests | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-66,003,637 |
| Net Income Discontinuous Operations | $0 | $0 | $0 | $-148,813 |
| Net Income Continuous Operations | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-65,854,824 |
| Pretax Income | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-65,854,824 |
| Special Income Charges | $-662,274 | $0 | $0 | $-46,575,032 |
| Interest Income Non Operating | $1,497,217 | $2,768,374 | $3,608,997 | $620,243 |
| Operating Income | $-60,689,539 | $-58,589,119 | $-14,391,685 | $-18,658,412 |
| Per Share | ||||
| Diluted EPS | $-0.62 | $-0.69 | $-0.10 | $-0.83 |
| Basic EPS | $-0.62 | $-0.69 | $-0.10 | $-0.83 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-53,407,930 | $-53,553,335 | $-9,210,497 | $33,540,839 |
| Total Unusual Items | $3,827,104 | $263,547 | $2,910,372 | $-47,489,493 |
| Total Unusual Items Excluding Goodwill | $3,827,104 | $263,547 | $2,910,372 | $-47,489,493 |
| Reconciled Depreciation | $5,783,256 | $2,265,137 | $1,572,191 | $51,579,008 |
| EBITDA (Bullshit earnings) | $-49,580,826 | $-53,289,789 | $-6,300,125 | $-13,948,654 |
| EBIT | $-55,364,082 | $-55,554,926 | $-7,872,316 | $-65,527,663 |
| Diluted Average Shares | $101,773,262 | $92,073,159 | $95,548,237 | $90,469,160 |
| Basic Average Shares | $101,773,262 | $92,073,159 | $95,548,237 | $90,469,160 |
| Diluted NI Availto Com Stockholders | $-55,863,911 | $-56,197,888 | $-8,599,341 | $-66,003,637 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $0 | $0 | $46,575,032 |
| Restructuring And Mergern Acquisition | $662,274 | - | - | - |
| Gain On Sale Of Security | $4,489,379 | $263,547 | $2,910,372 | $-914,461 |
| Research And Development | $49,551,291 | $59,048,053 | $63,639,670 | $58,687,949 |
| Selling General And Administration | $12,494,604 | $13,555,606 | $13,345,451 | $16,440,986 |
| Other Gand A | $3,456,776 | $3,836,192 | $3,301,147 | $4,821,084 |
| Salaries And Wages | $9,037,828 | $9,719,414 | $10,044,303 | $11,619,903 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-24,655,232 | $10,035,216 | $58,485,745 | $59,750,087 |
| Total Assets | $71,247,304 | $126,160,403 | $199,008,298 | $226,394,417 |
| Total Non Current Assets | $18,185,846 | $28,759,515 | $30,870,159 | $67,550,837 |
| Other Non Current Assets | $1,075,770 | $653,186 | $98,830 | $172,668 |
| Non Current Accounts Receivable | $285,130 | $10,596,388 | $11,989,095 | $16,016,131 |
| Investmentin Financial Assets | $11,876,633 | $11,678,973 | $11,128,025 | $39,894,355 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $11,876,633 | $11,678,973 | $11,128,025 | $39,894,355 |
| Goodwill And Other Intangible Assets | $0 | $0 | $472,566 | $1,764,171 |
| Current Assets | $53,061,458 | $97,400,888 | $168,139,275 | $158,844,716 |
| Other Current Assets | $1,136 | - | $1,136 | $2,272 |
| Prepaid Assets | $5,440,191 | $3,781,665 | $10,299,898 | $8,319,891 |
| Receivables | $8,644,780 | $1,866,409 | $52,810,407 | $35,237,988 |
| Other Receivables | $132,909 | $101,102 | $118,142 | $69,295 |
| Taxes Receivable | $8,067,704 | $1,026,923 | $35,387,937 | $31,669,886 |
| Accounts Receivable | $444,167 | $738,385 | $17,304,329 | $3,498,807 |
| Cash Cash Equivalents And Short Term Investments | $38,975,350 | $91,752,814 | $105,027,834 | $115,284,565 |
| Cash And Cash Equivalents | $31,911,849 | $75,424,289 | $80,205,614 | $95,677,612 |
| Non Current Deferred Assets | - | - | $10,230,603 | $9,733,046 |
| Non Current Deferred Taxes Assets | - | - | $10,230,603 | $9,733,046 |
| Other Intangible Assets | - | - | $472,566 | $1,764,171 |
| Debt | ||||
| Total Debt | $25,642,395 | $35,209,589 | $45,317,507 | $47,996,139 |
| Long Term Debt And Capital Lease Obligation | $15,643,531 | $25,316,370 | $35,166,421 | $45,608,316 |
| Long Term Debt | $15,533,341 | $25,198,229 | $34,768,830 | $44,222,425 |
| Current Debt And Capital Lease Obligation | $9,998,864 | $9,893,218 | $10,151,085 | $2,387,822 |
| Current Debt | $9,672,839 | $9,585,369 | $9,600,137 | $1,451,778 |
| Other Current Borrowings | $9,672,839 | $9,585,369 | $9,600,137 | $1,451,778 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $95,902,536 | $116,125,187 | $140,049,986 | $164,880,159 |
| Total Non Current Liabilities Net Minority Interest | $54,270,137 | $78,658,414 | $95,024,426 | $117,921,166 |
| Other Non Current Liabilities | $36,064,979 | $46,720,437 | $51,154,153 | $60,193,117 |
| Non Current Deferred Liabilities | $0 | $3,209,133 | $5,245,939 | $8,998,069 |
| Current Liabilities | $41,632,399 | $37,466,774 | $45,025,561 | $46,958,992 |
| Other Current Liabilities | $7,384,983 | $8,455,072 | $8,685,676 | $11,613,087 |
| Current Deferred Liabilities | $3,209,133 | $699,761 | $6,662,502 | $7,452,005 |
| Payables And Accrued Expenses | $17,087,357 | $18,183,574 | $19,332,046 | $23,754,403 |
| Payables | $17,087,357 | $18,183,574 | $19,332,046 | $23,754,403 |
| Other Payable | $1,159,832 | $1,274,566 | $1,631,262 | $1,450,642 |
| Total Tax Payable | $7,436,102 | $7,908,668 | $7,975,690 | $6,790,867 |
| Accounts Payable | $8,491,424 | $9,000,341 | $9,725,094 | $15,512,894 |
| Non Current Deferred Taxes Liabilities | - | - | $10,230,603 | $9,733,046 |
| Equity | ||||
| Common Stock Equity | $-24,655,232 | $10,035,216 | $58,958,311 | $61,514,258 |
| Total Equity Gross Minority Interest | $-24,655,232 | $10,035,216 | $58,958,311 | $61,514,258 |
| Stockholders Equity | $-24,655,232 | $10,035,216 | $58,958,311 | $61,514,258 |
| Gains Losses Not Affecting Retained Earnings | $1,270,022 | $30,671 | $562,308 | $930,365 |
| Other Equity Adjustments | $1,270,022 | $30,671 | $562,308 | $930,365 |
| Retained Earnings | $-494,765,433 | $-438,900,386 | $-382,702,497 | $-375,231,181 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $21,101 | $21,101 | $21,101 | - |
| Ordinary Shares Number | $106,441,838 | $95,208,183 | $91,834,590 | $90,358,547 |
| Share Issued | $106,462,939 | $95,229,283 | $91,855,691 | $90,358,547 |
| Tangible Book Value | $-24,655,232 | $10,035,216 | $58,485,745 | $59,750,087 |
| Invested Capital | $550,949 | $44,818,813 | $103,327,277 | $107,188,461 |
| Working Capital | $11,429,059 | $59,934,115 | $123,113,714 | $111,885,724 |
| Capital Lease Obligations | $436,215 | $425,991 | $948,540 | $2,321,936 |
| Total Capitalization | $-9,121,890 | $35,233,444 | $93,727,141 | $105,736,683 |
| Additional Paid In Capital | $463,515,858 | $444,142,917 | $436,504,612 | $431,258,673 |
| Capital Stock | $5,324,321 | $4,762,013 | $4,593,889 | $4,556,401 |
| Common Stock | $5,324,321 | $4,762,013 | $4,593,889 | $4,556,401 |
| Employee Benefits | $2,184,483 | $3,101,216 | $2,772,918 | $2,896,740 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,184,483 | $3,101,216 | $2,772,918 | $2,896,740 |
| Non Current Deferred Revenue | $0 | $3,209,133 | $5,245,939 | $8,998,069 |
| Long Term Capital Lease Obligation | $110,190 | $118,142 | $397,592 | $1,385,891 |
| Long Term Provisions | $377,144 | $311,258 | $684,994 | $224,923 |
| Current Deferred Revenue | $3,209,133 | $699,761 | $6,662,502 | $7,452,005 |
| Current Capital Lease Obligation | $326,025 | $307,850 | $550,949 | $936,045 |
| Current Provisions | $3,952,062 | $235,147 | $194,252 | $1,751,676 |
| Investments And Advances | $11,876,633 | $11,678,973 | $11,128,025 | $39,894,355 |
| Net PPE | $4,948,313 | $5,830,967 | $7,181,643 | $9,703,510 |
| Gross PPE | $4,948,313 | $5,830,967 | $7,181,643 | $9,703,510 |
| Construction In Progress | $0 | $0 | $0 | $0 |
| Other Properties | $2,709,304 | $3,235,261 | $3,821,425 | $4,884,699 |
| Land And Improvements | $2,239,009 | $2,595,706 | $3,360,218 | $4,818,812 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $7,063,501 | $16,328,525 | $24,822,220 | $19,606,953 |
| Leases | - | $1,441,554 | $1,902,760 | - |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,656,936 | $-8,277,860 | $-60,087,472 | $-23,034,193 |
| Operating Activities | ||||
| Operating Cash Flow | $-36,986,256 | $-7,833,693 | $-59,928,435 | $-21,759,628 |
| Cash Flow From Continuing Operating Activities | $-36,986,256 | $-7,833,693 | $-59,928,435 | $-21,759,628 |
| Operating Gains Losses | $349,881 | $-614,563 | $656,594 | $-621,379 |
| Investing Activities | ||||
| Capital Expenditure | $-2,670,681 | $-444,167 | $-159,037 | $-1,274,566 |
| Investing Cash Flow | $23,435,193 | $10,450,983 | $8,280,132 | $2,132,228 |
| Cash Flow From Continuing Investing Activities | $23,435,193 | $10,449,847 | $8,278,996 | $2,132,228 |
| Net Other Investing Changes | $71,567 | $1,136 | $6,816 | $-1,136 |
| Financing Activities | ||||
| Financing Cash Flow | $-2,233,330 | $-6,824,946 | $6,895,377 | $-2,076,565 |
| Cash Flow From Continuing Financing Activities | $-2,233,330 | $-6,824,946 | $6,895,377 | $-2,076,565 |
| Cash Dividends Paid | - | - | $0 | $0 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Other Financing Charges | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-2,682,040 | $-10,151,085 | $-10,122,686 | $-2,301,488 |
| End Cash Position | $80,205,614 | $75,424,289 | $31,911,849 | $95,677,612 |
| Beginning Cash Position | $95,677,612 | $80,205,614 | $75,424,289 | $117,864,367 |
| Effect Of Exchange Rate Changes | $311,258 | $-573,668 | $1,240,486 | $-486,198 |
| Changes In Cash | $-15,783,256 | $-4,207,657 | $-44,752,926 | $-21,700,557 |
| Proceeds From Stock Option Exercised | $448,711 | $3,326,139 | $17,018,062 | $224,923 |
| Net Issuance Payments Of Debt | $-2,682,040 | $-10,151,085 | $-10,122,686 | $-2,301,488 |
| Net Long Term Debt Issuance | $-2,682,040 | $-10,151,085 | $-10,122,686 | $-2,301,488 |
| Long Term Debt Payments | $-2,682,040 | $-10,151,085 | $-10,122,686 | $-2,301,488 |
| Interest Received Cfi | $0 | $0 | $440,759 | $0 |
| Net Investment Purchase And Sale | $25,863,911 | $10,894,014 | $7,991,594 | $3,407,929 |
| Sale Of Investment | $25,863,911 | $10,894,014 | $7,991,594 | $3,407,929 |
| Net Intangibles Purchase And Sale | $-2,271,953 | $0 | $0 | $-666,818 |
| Purchase Of Intangibles | $-2,271,953 | $0 | $0 | $-666,818 |
| Net PPE Purchase And Sale | $-228,331 | $-444,167 | $-159,037 | $-607,747 |
| Sale Of PPE | $170,396 | $0 | $0 | $0 |
| Purchase Of PPE | $-398,728 | $-444,167 | $-159,037 | $-607,747 |
| Change In Working Capital | $-36,455,755 | $44,487,108 | $-12,077,701 | $-14,203,113 |
| Other Non Cash Items | $6,816 | $-404,408 | $-402,136 | $151,085 |
| Stock Based Compensation | $4,834,716 | $4,480,291 | $2,916,051 | $4,826,764 |
| Unrealized Gain Loss On Investment Securities | $-1,808,474 | $-1,516,528 | $-512,325 | $1,558,560 |
| Provisionand Write Offof Assets | $-1,097,353 | $-332,841 | $3,782,801 | $953,084 |
| Depreciation Amortization Depletion | $5,783,256 | $2,265,137 | $1,572,191 | $51,579,008 |
| Depreciation And Amortization | $5,783,256 | $2,265,137 | $1,572,191 | $51,579,008 |
| Pension And Employee Benefit Expense | $323,753 | $368,056 | $-916,733 | $414,631 |
| Net Foreign Currency Exchange Gain Loss | $617,971 | $-1,005,339 | $1,547,200 | $-1,036,010 |
| Gain Loss On Sale Of PPE | $533,909 | $22,720 | $26,127 | $0 |
| Net Income From Continuing Operations | $-8,599,341 | $-56,197,888 | $-55,863,911 | $-66,003,637 |
| Issuance Of Debt | - | - | $0 | $0 |
| Interest Paid Cff | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Purchase Of Investment | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | - | $-26,618,199 |
| Change In Other Current Liabilities | - | - | - | $25,895,718 |
| Change In Payables And Accrued Expense | - | - | - | $-8,703,851 |
| Change In Payable | - | - | - | $-8,703,851 |
| Change In Account Payable | - | - | - | $-8,703,851 |
| Change In Receivables | - | - | - | $-4,775,645 |
| Changes In Account Receivables | - | - | - | $-4,775,645 |
| Gain Loss On Investment Securities | - | - | - | $-1,036,010 |
Fetched: 2026-06-24